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Abstract
In response to the fatal interaction of alcohol with extendedrelease hydromorphone, the U.S. Food and Drug Administration (FDA) approved a class-wide Risk Evaluation and
Mitigation Strategy (REMS) for extended-release (ER) and
long-acting (LA) opioid analgesics in July 2012. Due to the
rising concern of dose-dumping effects, it is important for
pharmacists to understand the pharmacokinetic interaction
between two of the most commonly prescribed LA opioids
(oxycodone and morphine) and alcohol. Clinical trials have
looked at the pharmacokinetic profile of these long-acting
formulations in conjunction with alcohol, and the results
have varied depending on the formulation. For this reason, it
is important to know which LA opioids have a serious interaction with alcohol so as to better serve the patient.
Introduction
Pharmacists, in evaluating a patient's response to drug
therapy, recognize drug interactions as a cause of toxicity or
inefficacy. As most drug interactions are based on pharmacokinetics (PK) or pharmacodynamics (PD), it is important to
understand and apply these relationships to daily practice.
One such drug relationship exists between alcohol and
opioids. Though there have been many studies showing the
pharacodynamic relationship between alcohol and opioids,
few have examined the pharmacokinetic interactions.1 With
the approval of the REMS for ER and LA opioids, now is a
critical time for pharmacists to understand the pharmacokinetics of alcohol and opioids and the harm associated with
their concomitant use.2 These interactions stem from the
overlap in metabolism of alcohol and opioids and the altered
pharmacokinetics, as is seen in patients with cirrhosis. With
an understanding of the pharmacokinetics of individual substances, the interaction can further be examined. Studies of
the pharmacokinetics of ER and LA morphine and oxycodone, two of the most commonly used opioids, have been
performed.1.3,4 These studies identified the importance of
examining the pharmacokinetics of the drug and determining
the influence of various formulations on concentration-time
relationships, all in the context of a patient's response to a
given dosage form. Once all of these factors have been examined, pharmacists will have the information necessary to
educate and monitor their patients.
The Alarm and the FDA Response
According to the 2007 National Survey on Drug Use and
Health, one-half of Americans 12 years of age and older report alcohol use.1 Opioids are also widely used by Americans.
While only constituting 4.6 percent of the world's population,
Americans consume nearly 80 percent of the world's opioid
supply.s When each of these substances are used responsibly
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and correctly, there are few concerns regarding drug interactions and patient safety. The true concern surfaces when
these substances are used concomitantly-whether intentionally or not. After a study performed on ER hydromorphone (Palladone®) showed a potentially fatal interaction
with alcohol, the FDA requested its removal from the market
in 2005,3.6 While actions, such as black box warnings (BBW)
seen in Table 1, have been provided to inform health care
providers of the potential toxicity due to the pharmacokinetic interaction between alcohol and opioids, the FDA has
only recently approved a more active approach to the issue.U In July of 2012, the FDA approved its first class-wide
REMS for ER and LA opioid analgesics. Introduced in March
of 2013, the current REMS features pharmacists as one of the
key contributors who will work with both prescribers and
patients to ensure correct use of these ER and LA opioids.2
The platform of patient education regarding the effects of
these ER and LA opioids with concomitant use of alcohol is
an important one for pharmacists and should not be overlooked. As the number of different ER and LA formulations of
opioid analgesics increases, and as altered liver function is
recognized in relation to drug metabolism, keeping current
with pharmacokinetic research for this issue is imperative
for patient care. With a proper understanding of how alcohol
affects the pharmacokinetics of a patient's ER or LA opioid
analgesic, the pharmacist may better help patients avoid dangerous adverse events and achieve the desired therapeutic
outcome.

Alcohol and the Liver
In order to appreciate the interaction between alcohol and
LA and ER opioids, the hepatic metabolism of alcohol must
be considered. Alcohol's metabolism involves many steps
and multiple enzymes. In the main pathway, alcohol is oxidized by alcohol dehydrogenase (ADH) to acetaldehyde, and
then further oxidized to acetate by aldehyde dehydrogenase
(ALDH) (Figure 1).7 ,a Acetaldehyde can bind to proteins and
form adducts. These adducts can impair protein secretion
and cause hepatomegaly.9 The major metabolic point where
alcohol and opioids interact is through cytochrome P-450
(CYP) enzymes. In the liver, CYP2El, 1A2, and 3A4 all contribute to alcohol oxidation.9 CYP2El metabolism in the
brain also oxidizes alcohol. The excess oxidation by CYP enzymes in the liver increases the oxygen consumption in the
liver. This can cause some areas of the liver to become hypoxic. The metabolism also causes the formation of reactive
oxygen species (ROS) in the liver. This oxidative stress along
with the hypoxia can cause acute liver damage and hepatitis
or cirrhosis with chronic use of alcohol.9.10
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Table 1. Long-acting Opioid Products and black box warning (BBW) for Alcohol.14-26
BBWfor
Alcohol:
Yes/No

Trade Name

Generic Name

Sponsor

Avinza

Morphine sulfate extended-release capsules

Pfizer

Yes

Butrans

Buprenorphine transdermal system

Purdue Pharma

No

Dolophine

Methadone hydrochloride tablets

Roxane

No

Duragesic

Fentanyl transdermal system

Janssen Pharmaceuticals

No

**Embeda

Morphine sulfate and naltrexone extended-release capsules

Pfizer

Yes

Exalgo

Hydromorphone hydrochloride extended-release tablets

Mallinckrodt

No

Kadian

Morphine sulfate extended-release capsules

Actavis

No

MS Cantin

Morphine sulfate controlled-release tablets

Purdue Pharma

No

Nucynta ER

Tapentadol extended-release oral tablets

Janssen Pharmaceuticals

Yes

Opana ER

Oxymorphone hydrochloride extended-release tablets

Endo Pharmaceuticals

Yes

OxyContin

Oxycodone hydrochloride controlled-release tablets

Purdue Pharma

No

*Palladone

Hydromorphone hydrochloride extended-release capsules

Purdue Pharma

Yes

*No longer being marketed, but is still approved.
**Not currently available due to a voluntary recall, but is still approved.

With progression of liver disease, the composition of the cirrhosis also impairs production of plasma proteins albumin
body changes, thereby changing the volume of distribution and a-acid glycoprotein. As a drug "becomes" a low extrac(Vd). Liver disease can also cause metabolic changes. Liver tion compound, its clearance switches from being dependent
failure with cirrhosis also alters the metabolic enzymes of on hepatic blood flow to being dependent on intrinsic clearthe liver. More significantly, liver disease affects phase I en- ance and fraction of unbound drug. With clearance dezymes, involved in oxidation-reduction reactions, more than creased and volume of distribution increased, the half-life
phase II enzymes which are involved in conjugation reac- gets longer.
tions.10 The phase I enzymes, including CYP enzymes, are
more sensitive to hypoxia, which is prevalent in liver disease. Figure 1. The Main Oxidative Metabolic Pathway of Alcohol.7
Hepatic metabolism is the primary elimination route for lipophilic drugs. Hepatic clearance is dependent upon hepatic
blood flow, plasma protein binding, and intrinsic clearance.
The hepatic extraction ratio (Eh) of the drug determines
which factors influence clearance most significantly.
Clearance of high extraction drugs with an Eh>O. 7 are mainly
dependent upon liver blood flow whereas low extraction
compounds with Eh<0.3 are mainly dependent upon plasma
protein binding and intrinsic metabolic clearance. 10 In
healthy patients, and in those with mild cirrhosis, morphine
is a high extraction compound with an Eh of approximately
0. 7, meaning hepatic blood flow will be the main contributor
to morphine's clearance. Therefore, when considering patients with chronic liver disease, morphine clearance is not
significantly altered until severe cirrhosis has developed.11 In
addition to altering hepatic blood flow, liver disease with
May 2013 Volume 4, Issue 2
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Alcohol and CR Oxycodone
To further understand the interaction between opioids and
alcohol, it is necessary to understand the kinetics of individual opioids. Each drug in the opioid class has its own set of
pharmacokinetic parameter values. Two opioids, oxycodone
and morphine, have pharmacokinetics profiles that have
been examined extensively.
Controlled-release (CR) oxycodone has become one of the
most commonly used CR opioids in the United States, making
it crucial to understand its kinetic interaction with alcohot.12
CR oxycodone is absorbed in a bi-exponential fashion. The
initial rapid phase has an absorption half-life of 37 minutes.
During this time, 38 percent of the drug is absorbed. The
rapid phase is then followed by a slow phase with an absorption half-life of 6.2 hours and duration of action of 12
hours.12,13 CR oxycodone bioavailability is 60 to 87 percent,
and it undergoes first-pass metabolism. Ten percent is metabolized through 0-demethylation by CYP2D6 to the minor
metabolite, oxymorphone, which is 14 times as potent as
oxycodone. Then, N-demethylation produces noroxycodone,
a weak analgesic that is the major metabolite of CR oxycodone.12 Because protein binding is relatively low, hepatic
cirrhosis and decreased plasma protein production will not
greatly affect Vd.
Recognizing the metabolism of both alcohol and CR oxycodone, one would conclude the interaction could be predicted. Results of recent clinical trials, however, have proven
otherwise. For example, Friedmann et al. 4 looked at the new
REMOXY (oxycodone) capsule. REMOXY is formulated to
have an increased viscosity to prevent crushing and decrease
"dose-dumping." As the capsule cannot be crushed, it cannot
be dissolved in alcohol to induce a euphoric high from quick
dissolution. The study found that there were no significant
changes in the pharmacokinetics of the formulation when
taken with 4 percent, 20 percent, or 40 percent alcohol
acutely. The researchers concluded that, while still not
recommended, concomitant use of alcohol and this new controlled-release formulation is safer compared to current formulations of CR oxycodone. This study exemplifies the need
to consider a medication's formulation when examining clinically important pharmacokinetics parameters.

Alcohol and ER morphine
In addition to CR oxycodone, ER morphine has been undergoing pharmacokinetic testing to examine its effects when
used with alcohol. Similar to CR oxycodone, ER morphine is
formulated to have an immediate release component upon
contact with GI fluids, followed by a sustained-release
component that generally lasts 12 to 24 hours.3 The bioavailability of oral morphine can increase from 40 percent to 100
percent in patients with severe cirrhosis.io.11 Furthermore,
while CR oxycodone is metabolized by CYP450 enzymes, ER
morphine is glucuronidated in the liver to two metabolites,
morphine-3-glucuronide (M3G) and to a lesser extent, morphine-6-glucuronide (M6G)

profile. When alcohol is used acutely and in reasonable
amounts with ER morphine, there is minor concern of increased opioid exposure. One product (Embeda) is a morphine sulfate ER capsule, which possesses a polymer around
the beads in the capsule to achieve extended release characteristics. When ingesting 240 mL of 20 percent alcohol
(similar to approximately 12 ounces of wine, a pint of beer,
or 2.5 glasses of a mixed drink) the rate of absorption and
the extent of exposure for morphine did not increase in patients. A change in pharmacokinetics was seen, however,
upon concomitant use of morphine extended-release and
240 mL of 40 percent alcohol. This amount of alcohol is
equivalent to five 1.5-ounce shots of hard liquor. Although
there was no change in bioavailability for morphine, the average maximum concentration (Cmax) was doubled and the
median time to maximum concentration (T max) was decreased from nine hours to four hours. Although this kinetic
profile may seem alarming, cumulative morphine exposure
while taking Embeda is not similar to that of an immediaterelease morphine solution combined with alcohol. This suggests that "dose dumping" is not particularly of concern
when mixing Embeda and acute alcohol use.1 However Embeda still has a BBW for alcohol use. Clinically, all interactions must be taken into account, including pharmacokinetics
and pharmacodynamics.
The effect of alcohol on the pharmacokinetics of another ER
morphine product, Kadian, has also been studied. Subjects in
the experimental groups were either given 100 mg ER morphine with 240 mL of 40 percent alcohol under fasting conditions or ingestion of a high-fat meal. The control received
100 mg of ER-morphine and 240 mL of water under fasting
conditions. All three groups had a Tmax of eight hours, and
the area under the curve (AUC) was similar between them as
well. Because the mean AUC and Cmax for each regimen were
within 80 percent to 125 percent, no drug interaction was
declared. Therefore, no BBW for Kadian and concomitant
alcohol consumption currently exists.3
The pharmacokinetic interaction of alcohol and opioids is
definitely intricate and multifactorial. Influenced by the separate pharmacokinetics of alcohol and opioids, cirrhosis and
its effect on hepatic metabolism, and the development of new
formulations, the subject can be difficult to understand.
Thus it is critical for pharmacists to be aware of these relationships and monitor patients appropriately. Newer CR
products like Embeda and Kadian are reducing the risks associated with this pharmacokinetic interaction. The REMS for
ER and LA opioids is leading the way by educating pharmacists and physicians of proper prescribing practices. To further advance pharmacist knowledge, continuing education
should be offered to pharmacists. With proper prescribing
and monitoring, LA and CR opioids can be used effectively in
all patients, regardless of their alcohol consumption.

Studies have been performed to evaluate the effects of alcohol combined with ER morphine and its pharmacokinetic
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